Navigation Links
Mother's immunosuppressive medications not likely to put fetus at risk
Date:11/8/2013

Women with chronic autoimmune diseases who take immunosuppressive medications during their first trimester of pregnancy are not putting their babies at significantly increased risk of adverse outcomes, according to a Vanderbilt study released online by the journal Arthritis and Rheumatism.

The paper is one of the first to describe risks for medications used to treat autoimmune diseases when taken during pregnancy, according to first author William Cooper, M.D., MPH, Cornelius Vanderbilt Professor of Pediatrics and professor of Health Policy at Monroe Carell Jr. Children's Hospital at Vanderbilt in Nashville, Tenn.

"This study is important because these conditions affect nearly 4.5 million persons in the U.S., including many women of childbearing age," Cooper said. "Currently, there are almost no data to guide women who are pregnant, or planning to become pregnant, who may need to continue their medications during pregnancy."

Study authors used health plan data from Tennessee Medicaid, Kaiser Permanente Northern California and Southern California, linked with vital records and medical records. The three geographically diverse health plans collectively provide coverage for more than 8 million persons each year.

The cohort included 608 infants, including 437 with exposure during pregnancy and 171 whose mothers filled prescriptions for immunosuppressives before, but not during, pregnancy.

Women with rheumatoid and psoriatic arthritis, ankylosing spondylitis, lupus, scleroderma, and inflammatory bowel disease who filled prescriptions for immunosuppressive treatments during pregnancy were included in the study.

The drugs studied included hydroxychloroquine, tumor necrosis factor (TNF) inhibitors and other immunosuppressives such as sulfasalazine and azathioprine.

When compared with the women who had medication treatment before, but not during, pregnancy the risk ratios for adverse fetal outcomes associated with immunosuppressive use during pregnancy were not statistically significant, the authors reported.

Cooper said some of the medications in the study are relatively new and therefore haven't been extensively used in pregnancy. As use continues to expand, follow-up studies will be important to ensure that new safety signals aren't detected.

"One of the things we find in studying drug exposures in pregnancy is that, because up to 50 percent of pregnancies are unplanned, women may be taking a medication and become pregnant while still taking a potentially harmful drug," Cooper said. "Therefore, it's very important for women who have conditions that require medical treatments to talk with their providers about potential risks of medications in pregnancy."


'/>"/>

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Concerns about MRSA for expectant mothers may be unfounded
2. Low-Income Mothers May Overfeed Their Infants
3. Canadian teen moms run higher risk of abuse, depression than older mothers
4. Study finds that single mothers can reduce stress by playing, engaging with children
5. Study suggests poor mothers favor daughters
6. Making bad worse for expectant mothers
7. New hospital guidelines to help mothers at risk of postpartum depression
8. Lower iron levels seen in newborns of obese mothers
9. Babies Born to Obese Mothers May Have Low Iron: Study
10. Study Ties Infant Birth Weight to Mothers Breast Cancer Risk
11. Pregnant Mothers Gut Changes May Support Fetal Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance ... beginning of a new charity campaign. As part of their ongoing community involvement ... In the belief that children deserve a voice, and in the spirit of ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley ... into Canada to provide its range of unique and advantaged protective solutions ... City that will provide bilingual customer service and marketing support. A new distribution ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare ... helpful interventions and causes of chronic illness in children. , Very recent articles have ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... Feb.8, 2016 Cardiovascular Surgery Devices - ... GlobalData,s Medical Devices sector report, "Cardiovascular Surgery Devices ... overview of Cardiovascular Surgery Devices currently in pipeline ... The report provides comprehensive information on the ... at various stages of development. The report reviews ...
(Date:2/8/2016)... FAIRFIELD, N.J. , Feb. 8, 2016  Otsuka ... today announced that they have entered into a licensing ... OPA-15406 in the U.S. and Puerto Rico ... is a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a ... --> --> In a Phase II ...
Breaking Medicine Technology: